Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib

BACKGROUND: Abivertinib is a novel oral, third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that overcomes T790M‐induced resistance in non‐small cell lung cancer (NSCLC) patients. Here, we report the results of a complete and detailed clinical data of patients t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Wang, Hanping, Pan, Ruili, Zhang, Xiaotong, Si, Xiaoyan, Wang, Mengzhao, Zhang, Li
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049520/
https://ncbi.nlm.nih.gov/pubmed/31943845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13302
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados